India Appeals Board Orders Fresh Review Of Pfizer's Sutent Patent
This article was originally published in PharmAsia News
An India appeals board has restored Pfizer's patent for its Sutent (sunitinib) cancer drug and ordered a new Patent Office review of the matter.
You may also be interested in...
Recent moves show Chinese biotech firms are increasingly looking to go global by recruiting world-class development talent, and J&J names new APAC pharma head.
Janet Woodcock’s 2019 prediction that record ANDA approval volumes would not continue is confirmed with the FY 2020 approval total down 21% from the previous year.
Deal snapshot: Resolving a loose end from its 2014 buyout of Auxilium, Endo acquires all rights to Xiaflex, along with approved cellulite therapy Qwo.